悪性神経膠腫化学療法のための研究—第1篇：in vitroのスクリーニング

EXPERIMENTAL AND CLINICAL STUDY OF BRAIN TUMOR CHEMOTHERAPY:PART 1: it vitro SCREENING

Ｉ．緒言

　悪性脳腫瘍，ことに悪性神経膠腫において，その外科的治療に限界がある以上，補助療法の占める比重は大きく，かつ将来益々その重要性を高めていくと考えられる。

　著者らはこの補助療法のうち化学療法に焦点を合せ実験的，臨床的検討を加えてきた。その目的とするところは，まず現状適用されている化学療法が脳腫瘍の正確な制癌作用をもたらしているか。他種腫瘍と比較し脳腫瘍への適応，選択性をどの程度維持しているかなどをふまえた正確な認識であつた。

Experimental and clinical studies of chemotherapy of malignant glioma were performed. In this report (part 1), the anti-brain tumor activity in vitro. of bleomycin, BCNU and cyclo-cytidine were verified using the cultured glioma cells.

The influence of the agents on these cells was judged by the growth curve and ³H-thym dine uptake.

Results :

1) These agents inhibited the growth curve of glioma cells (more than 50% of the control) at the concentration of 1-10 mcg/ml.

2) The cells of the faster cell cycle were more inhibited than the cells of slower cell cycle was done.

3) Even in the same cells, the inhibition of the growth rate was different in the different conditions. The cells in the better nutritional condition were more inhibited.

4) The most sensitive agent was different in each cell.

5) The dose response of each agent on the in- hibition of the growth rate was also different in each agents and cells.

6) The agents (BLM, BCNU and cyclo-cytidine) inhibited the ³H-thymidine uptake of these cells at the concentration of 1-10 mcgiml.

7) The degree of the inhibition observed by the ³H-thymidine uptake was almost the same with one seen by the growth curve.

These results indicated that the each cells and agent has its individuality, and DNA metabolism of these cells almost depended on the salvage pathway.

This fact suggested us the necessity of the screen-ing in vitro. of each clinical glioma.